Given that rs1805407 is associated with worse outcome of melanoma patients treated with TMZ and that PARP1 has a critical role in repair of DNA lesions caused by TMZ, one plausible hypothesis is that rs1805407 is either associated with increased PARP1 expression and/or activity or decreased PARP1 trapping after treatment with alkylating agents23–25. Here, PARP1 is linked to melanoma.